From GlobeNewswire: 2025-06-10 18:01:00

argenx presented positive Phase 2 results at EULAR 2025, showing efgartigimod improved muscle strength and function in myositis patients. The drug also reduced autoantibodies and improved outcomes in Sjogren’s disease, earning Fast Track designation from the FDA. Ongoing Phase 3 trials for myositis and Sjogren’s disease highlight efgartigimod’s potential as a precision therapy. Results from ALKIVIA study demonstrated significant improvements in muscle strength and physical function with efgartigimod treatment. RHO data revealed efgartigimod’s clinical effect in Sjogren’s disease, showing improved systemic disease activity and symptom reduction. Targeting FcRn and reducing IgGs could have a meaningful impact on Sjogren’s disease.



Read more at GlobeNewswire: argenx Presents New Efgartigimod Data at EULAR 2025